Why Is the FDA ‘Psyched’ on Psychedelics?
The U.S. Food and Drug Administration (FDA) recently announced national priority vouchers for studying several psychedelic drugs. This move follows an executive order by President Donald Trump to accelerate research into treatments for serious mental illness.
Which Psychedelics Are Approved for Study?
- Psilocybin — derived from “magic mushrooms,” being studied for depression and anxiety disorders.
- Methylone — a synthetic drug similar to MDMA, potentially for post-traumatic stress disorder (PTSD) therapy.
- Noribogaine hydrochloride — from the African iboga tree, researched for opioid addiction treatment.
Controversy and Outlook
Industry leaders welcome the FDA’s proactive stance, seeing hope for new mental health treatments. However, some experts worry that political pressure could compromise the agency’s traditional science-driven approval process, potentially affecting drug safety and efficacy assessments.
Overall, this ‘psychedelic renaissance’ is drawing global attention. Xiaoshu Health reminds readers that all drug research should follow scientific standards — patients should never self-administer unapproved psychedelic substances.